DHR vs. VTRS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DHR and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | DHR | VTRS |
|---|---|---|
| Company Name | Danaher Corporation | Viatris Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 149.76 billion USD | 12.14 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | December 29, 1978 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of DHR and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DHR | VTRS |
|---|---|---|
| 5-Day Price Return | 5.37% | 10.86% |
| 13-Week Price Return | 4.14% | 16.18% |
| 26-Week Price Return | -0.41% | -4.50% |
| 52-Week Price Return | -21.73% | -10.03% |
| Month-to-Date Return | 6.08% | 19.11% |
| Year-to-Date Return | -8.89% | -16.39% |
| 10-Day Avg. Volume | 3.84M | 11.44M |
| 3-Month Avg. Volume | 4.21M | 12.92M |
| 3-Month Volatility | 30.98% | 34.85% |
| Beta | 0.79 | 0.91 |
Profitability
Return on Equity (TTM)
DHR
6.69%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
DHR’s Return on Equity of 6.69% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
VTRS
-20.60%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
VTRS has a negative Return on Equity of -20.60%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
DHR
14.21%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
DHR’s Net Profit Margin of 14.21% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
VTRS
-26.45%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
VTRS has a negative Net Profit Margin of -26.45%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
DHR
18.43%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
DHR’s Operating Profit Margin of 18.43% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
VTRS
-27.18%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
VTRS has a negative Operating Profit Margin of -27.18%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | DHR | VTRS |
|---|---|---|
| Return on Equity (TTM) | 6.69% | -20.60% |
| Return on Assets (TTM) | 4.28% | -8.91% |
| Net Profit Margin (TTM) | 14.21% | -26.45% |
| Operating Profit Margin (TTM) | 18.43% | -27.18% |
| Gross Profit Margin (TTM) | 59.72% | 40.69% |
Financial Strength
Current Ratio (MRQ)
DHR
1.62
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
DHR’s Current Ratio of 1.62 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
VTRS
1.68
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
VTRS’s Current Ratio of 1.68 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
DHR
0.33
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
DHR’s Debt-to-Equity Ratio of 0.33 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
VTRS
0.91
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
VTRS’s Debt-to-Equity Ratio of 0.91 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
DHR
22.31
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
DHR’s Interest Coverage Ratio of 22.31 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
VTRS
-0.13
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | DHR | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 1.62 | 1.68 |
| Quick Ratio (MRQ) | 1.10 | 0.83 |
| Debt-to-Equity Ratio (MRQ) | 0.33 | 0.91 |
| Interest Coverage Ratio (TTM) | 22.31 | -0.13 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DHR
0.55%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Yield of 0.55% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
VTRS
5.22%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 5.22%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
DHR
23.85%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Payout Ratio of 23.85% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
VTRS
137.04%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | DHR | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.55% | 5.22% |
| Dividend Payout Ratio (TTM) | 23.85% | 137.04% |
Valuation
Price-to-Earnings Ratio (TTM)
DHR
43.76
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
DHR’s P/E Ratio of 43.76 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
VTRS
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for VTRS is currently unavailable.
Price-to-Sales Ratio (TTM)
DHR
6.22
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
DHR’s P/S Ratio of 6.22 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
VTRS
0.77
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.77 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
DHR
2.72
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
DHR’s P/B Ratio of 2.72 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
VTRS
0.66
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
VTRS’s P/B Ratio of 0.66 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | DHR | VTRS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 43.76 | -- |
| Price-to-Sales Ratio (TTM) | 6.22 | 0.77 |
| Price-to-Book Ratio (MRQ) | 2.72 | 0.66 |
| Price-to-Free Cash Flow Ratio (TTM) | 30.72 | 5.95 |